Compare BNZI & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNZI | PRPO |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 32.4M |
| IPO Year | N/A | N/A |
| Metric | BNZI | PRPO |
|---|---|---|
| Price | $1.60 | $24.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 521.0K | 7.2K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $10,650,176.00 | ★ $22,800,000.00 |
| Revenue This Year | $205.97 | N/A |
| Revenue Next Year | $31.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.06 | 30.95 |
| 52 Week Low | $0.92 | $3.90 |
| 52 Week High | $27.00 | $28.50 |
| Indicator | BNZI | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 63.69 | 47.31 |
| Support Level | $0.92 | $22.40 |
| Resistance Level | $1.08 | $24.92 |
| Average True Range (ATR) | 0.15 | 1.29 |
| MACD | 0.08 | -0.17 |
| Stochastic Oscillator | 63.80 | 30.04 |
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.